GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » PE Ratio

Johnson & Johnson (Johnson & Johnson) PE Ratio

: 10.16 (As of Today)
View and export this data going back to 1944. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-19), Johnson & Johnson's share price is $145.74. Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $14.34. Therefore, Johnson & Johnson's PE Ratio for today is 10.16.

Good Sign:

Johnson & Johnson stock PE Ratio (=10.55) is close to 10-year low of 10.55


The historical rank and industry rank for Johnson & Johnson's PE Ratio or its related term are showing as below:

JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.08   Med: 22.84   Max: 377.85
Current: 10.16


During the past 13 years, the highest PE Ratio of Johnson & Johnson was 377.85. The lowest was 10.08. And the median was 22.84.


JNJ's PE Ratio is ranked better than
81.21% of 612 companies
in the Drug Manufacturers industry
Industry Median: 23.03 vs JNJ: 10.16

Johnson & Johnson's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $14.34.

As of today (2024-04-19), Johnson & Johnson's share price is $145.74. Johnson & Johnson's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $10.07. Therefore, Johnson & Johnson's PE Ratio without NRI for today is 14.47.

During the past 13 years, Johnson & Johnson's highest PE Ratio without NRI was 23.89. The lowest was 14.36. And the median was 19.21.

Johnson & Johnson's EPS without NRI for the three months ended in Dec. 2023 was $2.29. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $10.07.

During the past 12 months, Johnson & Johnson's average EPS without NRI Growth Rate was 36.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 21.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.70% per year.

During the past 13 years, Johnson & Johnson's highest 3-Year average EPS without NRI Growth Rate was 107.40% per year. The lowest was -52.20% per year. And the median was 12.50% per year.

Johnson & Johnson's EPS (Basic) for the three months ended in Dec. 2023 was $-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $14.47.


Johnson & Johnson PE Ratio Historical Data

The historical data trend for Johnson & Johnson's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.91 28.56 21.90 26.25 11.42

Johnson & Johnson Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.43 33.51 11.56 11.42 At Loss

Competitive Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's PE Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's PE Ratio falls into.



Johnson & Johnson PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Johnson & Johnson's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=145.74/14.340
=10.16

Johnson & Johnson's Share Price of today is $145.74.
Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Johnson & Johnson  (NYSE:JNJ) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Johnson & Johnson PE Ratio Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson (Johnson & Johnson) Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Executives
Timothy Schmid officer: EVP, WW Chair, MedTech ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait officer: See Remarks ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo officer: VP, Worldwide Human Resources JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel officer: EVP, Chief GSC Officer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed officer: EVP, Pharmaceuticals R&D ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph J Wolk officer: Exec VP, CFO JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Ashley Mcevoy officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Robert J Decker officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard officer: Executive VP, General Counsel ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Darius Adamczyk director 855 S. MINT STREET, CHARLOTTE NC 28202
Vanessa Broadhurst officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933

Johnson & Johnson (Johnson & Johnson) Headlines